Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX-826 (Pyrilutamide) Phase 2 in Male Androgenetic Alopecia
NCT05218642Phase 2Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Jan 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Kintor Pharmaceutical Limited. Started Jan 2022; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05218642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218642.